Results 111 to 120 of about 10,275,652 (198)

Longitudinal Changes in Nutritional, Inflammatory, and CT-Derived Body Composition Markers During Adjuvant Chemotherapy for Stage II/III Colorectal Cancer. [PDF]

Cancers (Basel)
Hasegawa M, Momma T, Kimura S, Ichinose H, Yago H, Sato T, Ito M, Matsumoto T, Ujiie D, Chida S, Okayama H, Saito M, Sakamoto W, Kono K.   +13 more
europepmc   +1 more source

Impact of anti-HER2 therapies on potentially avoidable deaths from stage II and III HER2-positive breast cancer in the Brazilian public healthcare system. [PDF]

Breast
Mattar A, Cavalcante FP, Correa-Netto NF, Silveira I, Pavanel EB, La Scala CSK, Ziegelmann PK.   +6 more
europepmc   +1 more source

HistoNav: AI-Based H&E Histopathology Predicts Disease-Specific Survival and Guides Adjuvant Chemotherapy Decisions in Stage II/IIIA Colorectal Cancer. [PDF]

Cancers (Basel)
Xu X, Fotheringham S, Rajan S, Aliyev J, Kerr DJ.   +4 more
europepmc   +1 more source

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

JAMA Oncol
Tarantino P, Li T, Ogayo ER, Rahman T, DiLullo MK, Patel A, El-Refai S, Abbott C, Li B, Boyle SM, Chen RO, Desai NV, Spring LM, Tung NM, Sinclair N, Faggen M, Constantine M, King TA, Krop IE, Tayob N, Mittendorf EA, Tolaney SM, Winer EP, Parsons HA, Waks AG.   +24 more
europepmc   +1 more source

Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study. [PDF]

Cancer Immunol Immunother
De Falco V, Colloca A, Argenziano G, Scala M, Guida M, Ottaviano M, Sergi MC, Santarpia M, Del Giudice T, Grimaldi AM, Cozzolino S, Forte M, Caraglia F, Cioli E, Esposito A, Giugliano MC, Sparano F, Iovino F, Tolone S, Docimo G, Colella G, Faenza M, Franco R, Scharf C, Russo A, Formisano L, Ciardiello D, Ascierto PA, Ciardiello F, Troiani T.   +29 more
europepmc   +1 more source

Prognostic Value of the Vitamin B12/C-Reactive Protein Index in Resected Stage II-III Cutaneous Melanoma: Comparison with Its Individual Components. [PDF]

J Clin Med
Aktepe OH, Ekin O, Butun O, Izgor RB, Karaoglu A, Karabulut B, Yalcin S.   +6 more
europepmc   +1 more source

Neoadjuvant therapy for stage II-III triple-negative breast cancer: Current evidence, clinical boundaries and emerging strategies (Review). [PDF]

Oncol Lett
Li B, Tian X, Yu QQ, Cui H.
europepmc   +1 more source

Resectability and Neoadjuvant Chemoimmunotherapy in Stage II-III Non-Small Cell Lung Cancer: A European Case-Vignette Survey. [PDF]

Interdiscip Cardiovasc Thorac Surg
Lampridis S, Patel AJ, Josephides E, Doerr F, Zirafa CC, Hazer S, Obeso A, Bouabdallah I, Casiraghi M, Billè A.   +9 more
europepmc   +1 more source

Combining tertiary lymphoid structures and tumor stroma percentage for predicting prognosis and chemotherapy benefits in stage II-III colorectal cancer. [PDF]

BMC Cancer
Yang K, Li H, Dong X, Lin J, Li Z, Jiang W, Yan J.   +6 more
europepmc   +1 more source